Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Geny Piro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3708-5397; OpenAlex author ID A5048952935. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 21

  1. Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.2601788123↗
  2. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Co-author DOI 10.34133/cancomm.0030↗
  3. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  4. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
  5. The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Co-author DOI 10.1186/s13046-024-03263-w↗
  6. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  7. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  8. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
  9. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
  10. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Co-author DOI 10.3390/ijms24119313↗
  11. Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
  12. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  13. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… First author DOI 10.1136/jitc-2021-002876↗
  14. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. Co-author DOI 10.3389/fmed.2021.793144↗
  15. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0395↗
  16. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0270↗
  17. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. First author DOI 10.1038/ijo.2017.285↗
  18. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Co-author DOI 10.21873/anticanres.12431↗
  19. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. Co-author DOI 10.3390/ijms19113331↗
  20. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1322242↗
  21. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. First author DOI 10.3389/fphar.2013.00056↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carmine Carbone · 19 shared papers, 2013–2026 · strength 2.66
  2. Giampaolo Tortora · 15 shared papers, 2013–2026 · strength 2.02
  3. Vincenzo Corbo · 12 shared papers, 2021–2026 · strength 1.98
  4. Antonio Agostini · 11 shared papers, 2021–2026 · strength 1.83
  5. Francesco De Sanctis · 7 shared papers, 2021–2026 · strength 1.16
  6. Aldo Scarpa Scarpa · 9 shared papers, 2017–2025 · strength 1.07
  7. Alessia Caggiano · 5 shared papers, 2022–2026 · strength 0.86
  8. Alberto Larghi · 4 shared papers, 2021–2025 · strength 0.59
  9. Vincenzo Bronte · 3 shared papers, 2024–2026 · strength 0.56
  10. Davide Melisi · 7 shared papers, 2013–2020 · strength 0.55
  11. Raffaela Santoro · 6 shared papers, 2017–2020 · strength 0.51
  12. Francesca Lupo · 3 shared papers, 2024–2025 · strength 0.48
  13. Gian Luca Rampioni Vinciguerra · 2 shared papers, 2026 · strength 0.46
  14. Rita Teresa Lawlor · 3 shared papers, 2023–2024 · strength 0.46
  15. Pietro Delfino · 3 shared papers, 2021–2024 · strength 0.42
  16. Giuseppe Quero · 3 shared papers, 2021–2023 · strength 0.39
  17. Sergio Alfieri · 3 shared papers, 2021–2023 · strength 0.39
  18. Claudio Sette · 2 shared papers, 2021–2026 · strength 0.34
  19. Claudio Bassi · 3 shared papers, 2017–2025 · strength 0.33
  20. Francesca Simionato · 4 shared papers, 2017–2020 · strength 0.33
  21. Valeria Merz · 4 shared papers, 2017–2020 · strength 0.33
  22. Francesco Spallotta · 2 shared papers, 2021–2025 · strength 0.31
  23. Sabrina L. D’Agosto · 2 shared papers, 2024 · strength 0.31
  24. Lisa Veghini · 2 shared papers, 2024 · strength 0.31
  25. Elena Fiorini · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.